Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of “Hold” from Analysts

Arvinas, Inc. (NASDAQ:ARVN) has earned an average rating of “Hold” from the nineteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $13.8824.

A number of brokerages have recently weighed in on ARVN. Wedbush raised their price objective on shares of Arvinas from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Tuesday, February 24th. Piper Sandler reiterated an “overweight” rating and set a $20.00 target price (up from $16.00) on shares of Arvinas in a research note on Wednesday, February 25th. BTIG Research increased their target price on Arvinas from $14.00 to $16.00 and gave the company a “buy” rating in a report on Thursday. Truist Financial set a $10.00 price target on Arvinas in a research note on Wednesday. Finally, Wall Street Zen downgraded Arvinas from a “hold” rating to a “sell” rating in a report on Monday, March 2nd.

Insider Buying and Selling at Arvinas

In other Arvinas news, Director Briggs Morrison bought 20,000 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The stock was purchased at an average price of $13.40 per share, for a total transaction of $268,000.00. Following the completion of the purchase, the director directly owned 96,021 shares in the company, valued at $1,286,681.40. This trade represents a 26.31% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew Saik sold 5,134 shares of the company’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $11.89, for a total value of $61,043.26. Following the completion of the transaction, the chief financial officer directly owned 159,267 shares of the company’s stock, valued at $1,893,684.63. This trade represents a 3.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 63,864 shares of company stock worth $802,443. 4.73% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ARVN. Tower Research Capital LLC TRC raised its stake in Arvinas by 491.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock worth $43,000 after acquiring an additional 4,835 shares in the last quarter. Canada Pension Plan Investment Board boosted its stake in Arvinas by 109.4% in the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock valued at $49,000 after acquiring an additional 3,500 shares in the last quarter. State of Wyoming acquired a new position in Arvinas in the third quarter valued at $68,000. Abel Hall LLC purchased a new position in shares of Arvinas during the fourth quarter worth about $125,000. Finally, Corient Private Wealth LLC purchased a new position in shares of Arvinas during the fourth quarter worth about $127,000. 95.19% of the stock is owned by hedge funds and other institutional investors.

Arvinas Stock Performance

ARVN stock opened at $10.94 on Friday. The company’s 50 day moving average price is $12.70 and its 200 day moving average price is $11.17. Arvinas has a fifty-two week low of $5.90 and a fifty-two week high of $14.51. The firm has a market capitalization of $699.72 million, a price-to-earnings ratio of -8.55 and a beta of 1.87.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.55). Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.The firm had revenue of $9.50 million during the quarter, compared to analysts’ expectations of $37.26 million. During the same quarter in the prior year, the firm earned ($0.63) EPS. The firm’s revenue was down 84.0% compared to the same quarter last year. Equities analysts forecast that Arvinas will post -3.81 EPS for the current fiscal year.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.